Skip to main content
CHRS
NASDAQ Life Sciences

LOQTORZI Revenue Jumps 61% in Q1, Coherus Oncology Advances Key Pipeline Programs

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$1.89
Mkt Cap
$300.724M
52W Low
$0.71
52W High
$2.616
52W Position info
166% above low
Off High info
28% below high
Rel. Volume info
2.6× avg
Market data snapshot near publication time

CHRS has more than doubled off its 52-week low of $0.71 on elevated volume (2.6× avg).

Summary

Coherus Oncology reported strong first-quarter 2026 financial results, with LOQTORZI net revenue reaching $11.8 million, marking a 61% increase year-over-year. The company also ended the quarter with a solid cash position of $167.0 million. This positive financial update follows the company's strategic pivot to focus exclusively on oncology, as outlined in its recent 10-K filing. Furthermore, Coherus provided encouraging business updates on its pipeline, confirming patient accrual completion for the 1L HCC Phase 2 trial for casdozokitug and continued development for tagmokitug, with multiple data readouts expected throughout 2026. Traders will be watching for these upcoming data readouts, particularly for casdozokitug around mid-year and tagmokitug in mid-2026 and 2H 2026, as well as the anticipated initiation of the pasritamig combination study in the fall.

At the time of this announcement, CHRS was trading at $1.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $300.7M. The 52-week trading range was $0.71 to $2.62. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

CHRS - Latest Insights

CHRS
Nov 09, 2026, 4:59 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.8008
Real-time Price: $0.4942 info
Change: -$0.3066 (-38%) info
Market Cap: $76.357M info
CHRS
Nov 09, 2026, 4:20 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.7976
Real-time Price: $0.4942 info
Change: -$0.3034 (-38%) info
Market Cap: $76.357M info
CHRS
Nov 09, 2026, 4:07 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $0.770
Real-time Price: $0.4942 info
Change: -$0.2758 (-36%) info
Market Cap: $76.357M info
CHRS
Oct 29, 2026, 8:10 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.05
Real-time Price: $0.4942 info
Change: -$0.5558 (-53%) info
Market Cap: $76.357M info
CHRS
Sep 23, 2026, 1:01 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $1.25
Real-time Price: $0.4942 info
Change: -$0.7508 (-60%) info
Market Cap: $76.357M info